A prospective randomized study of CHOP versus CHOP plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: The International Oncology Study Group NHL1 study

Author
Hamza, R
Ferhanoglu, B
Khalid, HM
Intragumtornchai, T
Kim, SW
Kim, SY
Koc, H
Kumar, L
Kumar, R
Lei, KI
Lekhakula, A
Muthalib, A
Patel, M
Poovalingam, VP
Prayoonwiwat, W
Rana, F
Reksodiputro, AH
Ruff, P
Sagar, TG
Schwarer, AP
Song, HS
Suh, CW
Suharti, C
Supindiman, I
Tee, GY
Thamprasit, T
Villalon, AH
Wickham, NR
Wong, JE
Yalcin, A
Jootar, S
Giles, FJ
Shan, JQ
Advani, SH
Akan, H
Aydogdu, I
Aziz, Z
Azim, HA
Bapsy, PP
Buyukkececi, F
Chaimongkol, B
Chen, PM
Cheong, SK
Metadata
Show full item record
Abstract
The addition of a brief alpha interferon regimen to each CHOP induction cycle, plus one year of alpha interferon thrice weekly maintenance therapy, has no early effect on response rates or survival in patients with Intermediate or High grade cell NHL.
URI
http://hdl.handle.net/20.500.12627/79872
https://doi.org/10.3109/10428190009054885
Collections